



## **Aurobindo Pharma receives five new registrations from MCC – South Africa**

Aurobindo Pharma Ltd is pleased to announce that Medicines Control Council (MCC) South Africa has granted approval to manufacture and market five more products in South Africa

The products approved are as follows:

<b>S.no</b>	<b>Product Name</b>	<b>Dosage Form</b>	<b>Active Ingredient</b>	<b>Category</b>
1.	AURO-ABACAVIR 300mg	Tablet	Abacavir	ARV
2.	Auro-abacavir 20mg/ml	Oral Solution	Abacavir	ARV
3.	Auroprozil 250mg & 500mg	Tablet	Cefprozil	Anti-infective
4.	Auro-cefotaxime 250mg, 500mg, 1000mg & 2000mg	Injection	Cefotaxime	Anti-infective
5.	AURO-CEFALEXIN 250mg & 750mg	Tablet	Cefalexin	Anti-infective

Aurobindo now has a total of 36 registrations approved by the MCC

### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..